Celyad Oncology S.A.
CLYYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -91.9% | 1,128.6% | -75.9% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -1,414.3% | -30.2% | 35.7% | 56.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -25,775% | -1,512.8% | -19,921.4% | -7,703.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26,428.6% | -1,615.7% | -21,742.9% | -8,117.2% |
| EPS Diluted | -0.089 | -0.067 | -0.12 | -0.16 |
| % Growth | -33.2% | 44.1% | 25% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |